[go: up one dir, main page]

MX2018012655A - Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. - Google Patents

Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.

Info

Publication number
MX2018012655A
MX2018012655A MX2018012655A MX2018012655A MX2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A
Authority
MX
Mexico
Prior art keywords
compounds
methods
treating neurological
cardiovascular conditions
conditions
Prior art date
Application number
MX2018012655A
Other languages
English (en)
Other versions
MX391725B (es
Inventor
S Korinek William
D Lechleiter James
E Liston Theodore
A Jacobson Kenneth
Original Assignee
Astrocyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrocyte Pharmaceuticals Inc filed Critical Astrocyte Pharmaceuticals Inc
Publication of MX2018012655A publication Critical patent/MX2018012655A/es
Publication of MX391725B publication Critical patent/MX391725B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos y métodos de uso de los mismos para el tratamiento de ciertos trastornos y afecciones, por ejemplo, lesiones cerebrales tales como accidente cerebrovascular o lesiones cerebrales traumáticas.
MX2018012655A 2016-04-21 2017-04-21 Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. MX391725B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325860P 2016-04-21 2016-04-21
PCT/US2017/028996 WO2017185061A1 (en) 2016-04-21 2017-04-21 Compounds and methods for treating neurological and cardiovascular conditions

Publications (2)

Publication Number Publication Date
MX2018012655A true MX2018012655A (es) 2019-09-06
MX391725B MX391725B (es) 2025-03-21

Family

ID=60022855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012655A MX391725B (es) 2016-04-21 2017-04-21 Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.

Country Status (12)

Country Link
US (7) US9789131B1 (es)
EP (2) EP3445368B1 (es)
JP (3) JP7109005B2 (es)
KR (2) KR20220132042A (es)
CN (2) CN114903903A (es)
AU (2) AU2017254720B2 (es)
CA (1) CA3020490A1 (es)
EA (1) EA201892008A1 (es)
ES (1) ES2989621T3 (es)
IL (2) IL262487B (es)
MX (1) MX391725B (es)
WO (1) WO2017185061A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120628C2 (uk) 2014-11-07 2020-01-10 Басф Се Пестицидні суміші
US10905122B2 (en) 2016-03-16 2021-02-02 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on cereals
BR112018068695B1 (pt) 2016-03-16 2022-12-27 Basf Se Uso de um composto e método para controlar fungos fitopatogênicos
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
MX391725B (es) 2016-04-21 2025-03-21 Astrocyte Pharmaceuticals Inc Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
JP7311855B2 (ja) * 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド 嗜癖および関連する障害を処置するための化合物および方法
WO2019232554A2 (en) * 2018-05-26 2019-12-05 Primetime Life Sciences, Llc Compounds and methods for modulation of g-protein-coupled receptors
WO2020061211A1 (en) * 2018-09-18 2020-03-26 Saint Louis University Use of highly-selective adenosine 3a receptor subtype agonists
EP3856741A4 (en) * 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
JP7282324B2 (ja) * 2018-12-11 2023-05-29 株式会社島津製作所 イオン化装置、質量分析装置および流体試料の分析方法
US20220218712A1 (en) * 2019-02-25 2022-07-14 Saint Louis University Treatment of alzheimer's disease
AU2019444412B2 (en) * 2019-05-06 2025-02-20 Ferrer Internacional, S.A. Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and B vitamins, preparation and uses thereof
WO2022232810A1 (en) * 2021-04-28 2022-11-03 Astrocyte Pharmaceuticals, Inc. Purine nucleosides, their intermediates, and methods of preparation thereof
CN118414152A (zh) * 2021-11-22 2024-07-30 阿斯特罗赛特制药公司 治疗神经系统和心血管病状的方法
EP4611765A2 (en) * 2022-11-03 2025-09-10 Astrocyte Pharmaceuticals, Inc. Fast-dissolving dosage forms and uses thereof
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69428536T2 (de) 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
WO2001051490A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
ATE292973T1 (de) 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
AU2002359732A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
GB0209539D0 (en) 2002-04-26 2002-06-05 Avecia Ltd Monomer Polymer and process
EP1624753B1 (en) 2002-11-21 2012-01-25 The University of Utah Research Foundation Purinergic modulation of smell
DK1699459T3 (da) 2003-12-29 2007-10-08 Can Fite Biopharma Ltd Fremgangsmåde til behandling af multipel sclerose
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
KR20070050484A (ko) 2004-09-09 2007-05-15 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Ａ1 및 ａ3 아데노신 수용체 아고니스트로서의 퓨린 유도체
WO2006091905A1 (en) * 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
WO2007139775A2 (en) 2006-05-23 2007-12-06 University Of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20100047798A1 (en) 2006-11-08 2010-02-25 Thomas Jefferson University Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome
WO2008156513A2 (en) 2007-03-29 2008-12-24 University Of Connecticut Methods to protect skeletal muscle against injury
US20090088403A1 (en) 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
DE102007055529A1 (de) 2007-08-06 2009-02-12 Rhode & Schwarz Gmbh & Co. Kg Verfahren und Anordnung zum Erzeugen eines frequenzmodulierten Signals
WO2009050707A1 (en) 2007-10-15 2009-04-23 Can-Fite Biopharma Ltd. Method for inducing hepatocyte proliferation and uses thereof
JP2011500631A (ja) 2007-10-17 2011-01-06 ノバルティス アーゲー アデノシンａ１受容体リガンドとしてのプリン誘導体
US20100256086A1 (en) 2007-11-23 2010-10-07 Bar-Ilan Univetrsity Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
EP2260038B1 (en) * 2008-03-31 2014-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
RU2499592C2 (ru) 2008-04-21 2013-11-27 Отономи, Инк. Фармацевтическая композиция для лечения ушных заболеваний
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
US8685372B2 (en) 2009-04-15 2014-04-01 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
EP2507241A1 (en) 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
WO2011103552A2 (en) 2010-02-22 2011-08-25 University Of Connecticut Compositions and methods to treat cardiac diseases
WO2011133580A1 (en) 2010-04-19 2011-10-27 Back Bay Scientific Llc Use of drugs that activate p2y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
WO2013049725A2 (en) 2011-09-30 2013-04-04 Tufts University Methods of using adenosine a1 receptor activation for treating depression
AU2014243707B2 (en) 2013-03-13 2018-08-30 Tufts University Uridine nucleoside derivatives, compositions and methods of use
US20150087613A1 (en) 2013-09-26 2015-03-26 Saint Louis University Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy
WO2015080940A1 (en) 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
CN104873531B (zh) * 2015-05-06 2019-04-23 浙江省亚热带作物研究所 一种腺苷受体激动试剂及其用途
US20160024135A1 (en) 2014-07-27 2016-01-28 Zhejiang Subtropical Crops Research Institute Adenosine receptor activation reagent and the uses of thereof
WO2016123672A1 (en) 2015-02-04 2016-08-11 Baker Idi Heart & Diabetes Institute Holdings Limited A method of treatment and compounds for use therein
WO2016138066A1 (en) 2015-02-24 2016-09-01 Glaxosmithkline Intellectual Property Development Limited Neuromodulation device
MX391725B (es) 2016-04-21 2025-03-21 Astrocyte Pharmaceuticals Inc Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
CN109790164B (zh) 2016-07-25 2022-01-25 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
JP7311855B2 (ja) 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド 嗜癖および関連する障害を処置するための化合物および方法
KR102602990B1 (ko) 2018-06-27 2023-11-17 에스케이하이닉스 주식회사 전원 공급 장치 및 이를 포함하는 전자 장치
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
AU2020320876B2 (en) 2019-07-27 2025-09-25 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2022232810A1 (en) 2021-04-28 2022-11-03 Astrocyte Pharmaceuticals, Inc. Purine nucleosides, their intermediates, and methods of preparation thereof
CN118414152A (zh) 2021-11-22 2024-07-30 阿斯特罗赛特制药公司 治疗神经系统和心血管病状的方法

Also Published As

Publication number Publication date
AU2023202694B2 (en) 2025-07-10
KR102445887B1 (ko) 2022-09-21
CN114903903A (zh) 2022-08-16
AU2023202694A1 (en) 2023-05-18
NZ747047A (en) 2025-02-28
EP3445368A1 (en) 2019-02-27
CA3020490A1 (en) 2017-10-26
KR20190006501A (ko) 2019-01-18
US12239654B2 (en) 2025-03-04
IL289423A (en) 2022-02-01
ES2989621T3 (es) 2024-11-27
EP3445368A4 (en) 2019-12-18
WO2017185061A1 (en) 2017-10-26
KR20220132042A (ko) 2022-09-29
BR112018071560A2 (pt) 2019-02-12
EA201892008A1 (ru) 2019-06-28
US20230165887A1 (en) 2023-06-01
US20250345353A1 (en) 2025-11-13
IL262487B (en) 2022-02-01
EP4414027A3 (en) 2024-11-13
US20220305044A1 (en) 2022-09-29
AU2017254720A1 (en) 2018-11-01
IL262487A (en) 2018-12-31
MX391725B (es) 2025-03-21
AU2017254720B2 (en) 2023-02-02
JP7709141B2 (ja) 2025-07-16
JP7109005B2 (ja) 2022-07-29
EP3445368C0 (en) 2024-07-17
US20200046751A1 (en) 2020-02-13
US20220000899A1 (en) 2022-01-06
EP4414027A2 (en) 2024-08-14
US10953031B2 (en) 2021-03-23
US12390483B2 (en) 2025-08-19
CN109310695A (zh) 2019-02-05
US20180021363A1 (en) 2018-01-25
US9789131B1 (en) 2017-10-17
JP2022088642A (ja) 2022-06-14
US10265338B2 (en) 2019-04-23
IL289423B1 (en) 2025-11-01
EP3445368B1 (en) 2024-07-17
JP2019515920A (ja) 2019-06-13
JP2025084908A (ja) 2025-06-03
US11484545B2 (en) 2022-11-01
CN109310695B (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
DOP2018000040A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
UY37018A (es) Inhibidores bicíclicos de pad4
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
NI201700071A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
MX378108B (es) Anticuerpos anti-met y composiciones.
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
UY36741A (es) Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
CO2019013317A2 (es) Oligonucleótidos antisentido para la modulación de la expresión de htra1
CL2017002304A1 (es) Métodos para tratar enfermedades
MX2017009608A (es) Compuestos anticancerigenos.
BR112017025264A2 (pt) tratamento de prurido
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
MX2020008138A (es) Formulaciones parentales y usos de estas.
CO2018005354A2 (es) Derivados novedosos de diamino piridina